Editor's key points † Changes in energy metabolism in response to sevoflurane, propofol, or Intralipid were measured in working rat hearts after ischaemia and reperfusion. † Sevoflurane, but not propofol, improved the recovery of heart function and decreased calcium overload via enhanced glucose uptake. † This study begins to explain the mechanisms behind the cardioprotective effects of sevoflurane.
proliferator-activated receptor-regulated gene products involved in FOX (long-term effects). 4 In contrast, propofol (100 mM) increases GOX by dephosphorylating the pyruvate dehydrogenase (PDH) complex, elevates formation of lipotoxic ceramides, and inhibits 3-hydroxy-acyl-coenzyme A (CoA) dehydrogenase, a critical enzyme of mitochondrial b-oxidation. 3 So far, however, no study has directly measured the metabolic effects of sevoflurane and propofol on flux rates of glucose and fatty acids in hearts subjected to ischaemia -reperfusion injury. On the basis of our previous results, we hypothesized that the two anaesthetics for which cardioprotective properties were reported in the past 5 -8 would differentially modulate cardiac metabolism under ischaemiareperfusion conditions and that changes in metabolism could be related to measured intracellular Ca 2+ overload.
Beat-to-beat Ca 2+ recordings and contractility in the working rat heart model served as outcome measures and were related to changes in energy metabolism and metabolites.
Methods
Working heart perfusion protocols and beat-to-beat intracellular Ca 21 measurements
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and the experimental protocol used in this investigation was approved by the University of Alberta Animal Policy and Welfare Committee. Male Sprague -Dawley rats (350 -400 g), treated according to the guidelines of the University of Alberta Animal Policy and Welfare Committee and the Canadian Council on Animal Care, were killed with an overdose of pentobarbital (150 mg kg 21 , i.p.). Each heart was rapidly removed and perfused initially (15 min) in a nonworking Langendorff mode with the Krebs -Henseleit solution. Working mode perfusion was subsequently established (11.5 mm Hg preload, 80 mm Hg afterload, 5 Hz) with a recirculating perfusate (100 ml, 378C, pH 7.4, gassed with 95% O 2 /5% CO 2 ) that consisted of a modified Krebs-Henseleit solution containing (mM): KCl (4.7), NaCl (118), KH 2 PO 4 (1.2), MgSO 4 (1.2), CaCl 2 (2.5), NaHCO 3 (25) , glucose (11) , palmitate (1.2, pre-bound to 3% bovine serum albumin), and insulin 100 mU litre 21 . To determine beat-to-beat intracellular 10 Samples were obtained every 10 min and rates were calculated for each time interval and were averaged for the pre-and post-ischaemic period. Subsequently, the difference between averaged preischaemic and averaged post-ischaemic values was computed.
Determination of nucleotides and ceramides
Adenine nucleotides and ceramides were measured after tissue extraction using high-performance liquid chromatography, as described previously. 3 The energy charge of the adenylate pool was computed as (ATP+0.5 ADP)/ (ATP+ADP+AMP).
Mass spectrometry for acylcarnitine profiling
From four randomly chosen hearts of each group, tissue levels of 32 acylcarnitine species were measured using electrospray ionization tandem mass spectrometry. 3 Acylcarnitines were extracted from heart tissue with methanol and quantified using eight isotopically labelled internal standards (Cambridge Isotopes Laboratories, Andover, MA, USA and metabolic data were obtained, and western blotting was performed as described previously. 
Statistical analysis
The sample size was calculated based on previously reported data for the recovery of left ventricular function and changes in GOX and diastolic Ca 2+ concentrations. 9 With an expected difference of 50% between group means, 20% SD of the means, the significance level a¼0.05/3 (Bonferroni's correction for three groups since PROP100+IR was compared with IR and INTRA100+IR), and b¼0.8, a sample size of five hearts per group was necessary. The significance of differences in haemodynamic and metabolic variables among groups was determined by Student's t-test (two groups) or by analysis-of-variance (ANOVA) followed by the Student -Newman -Keuls method for post hoc analysis (three groups) or by non-parametric methods (WilcoxonMann-Whitney rank-sum test and Kruskal-Wallis analysis-of-variance on ranks) depending on the underlying data distribution. To test the association between GOX and changes in intracellular Ca 2+ concentrations, linear regression analysis was performed. The correlation coefficient R, the standard error of the estimate, and the corresponding P-value are reported. Differences are considered significant if P,0.05. SigmaStat (version 3.5; Systat Software, Inc., Chicago, IL, USA) was used for the analyses.
Results
Sevoflurane but not propofol reduces Ca 21 overload and increases myocardial efficiency after ischaemiareperfusion injury in working hearts . IR, hearts exposed to ischaemia -reperfusion; SEVO+IR, hearts exposed to ischaemia -reperfusion and treated with 2 vol% sevoflurane before and after ischaemia; PROP100+IR, hearts exposed to ischaemia -reperfusion and treated with 100 mM propofol before and after ischaemia; INTRA100+IR, the corresponding Intralipid control group. Complete haemodynamic data were obtained for six hearts in each group except for IR and INTRA100+IR with only five hearts (also see Supplementary  Table S1 ). Complete metabolic data were obtained in six hearts of each group except for IR and SEVO+IR with five hearts and INTRA+IR with four hearts. P-values were computed using nonparametric tests. ischaemia and 30 min of reperfusion, the decrease in LVW (P¼0.008), peak systolic pressure (P¼0.035), and stroke volume (P¼0.016) was significantly smaller in sevofluranetreated hearts when compared with untreated control hearts ( Fig. 1A; Supplementary Table S1 ). In contrast, propofol was not protective when compared with untreated control hearts or Intralipid (P¼0.41). Myocardial efficiency was higher in sevoflurane-treated hearts (P¼0.008), but was depressed to a similar extent in propofol-treated and untreated hearts (P¼0.64; Fig. 1B 
Sevoflurane but not propofol increases GOX after ischaemia -reperfusion injury in working hearts
Determinations of GOX, FOX, and Krebs cycle acetyl-CoA production rates after ischaemia -reperfusion injury revealed an increase in GOX in sevoflurane-treated hearts when compared with untreated control hearts (P¼0.009) ( Fig. 3A ; Supplementary Table S3 ). In accordance with our previous report, sevoflurane-treated hearts also showed a significant decrease in FOX (P¼0.016; Fig. 3B ) and a corresponding decline in acetyl-CoA production (P¼0.03; Fig. 3C ). Lower peak ischaemic Ca 2+ concentrations (P¼0.002) and changes in diastolic (P¼0.002) and systolic (P¼0.005) Ca 2+ concentrations were closely correlated with higher GOX (Fig. 4) . No changes in GOX (P¼0.45), FOX rate (P¼0.43), or acetyl-CoA turnover (P¼0.45) were observed in propofol-and Intralipid-treated hearts during reperfusion ( Fig. 3 ; Supplementary Table S3) . Levels of triglycerides were markedly reduced in sevoflurane-(P¼0.044) but not propofol-treated hearts (P¼0.51; Supplementary Table S4 ), suggesting reduced fatty acid uptake, as previously shown. D) in untreated hearts (IR, n¼5) or in hearts that were exposed to sevoflurane (2 vol%, SEVO+IR, n¼6), propofol (100 mM, PROP100+IR, n¼6), or Intralipid (INTRA100+IR, n¼5). P-values were computed using non-parametric tests.
Sevoflurane increases GLUT4 expression in lipid rafts in an AMPK-independent manner after ischaemiareperfusion injury in working hearts
To further explore the mechanism of the sevoflurane-induced increase in GOX, the expression of functional, that is, lipid raft-associated GLUT4 was determined in working hearts exposed to ischaemia-reperfusion. Sevoflurane-treated hearts exhibited higher GLUT4 expression in lipid rafts when compared with untreated control hearts (P¼0.019; Fig. 5A ), which was not related to increased activity of AMPK (P¼0.72; Fig. 5B ). Also, sevoflurane did not change the activity of the PDH complex (PDC; P¼0.22; Fig. 5C ). Total glycogen content and radioactively labelled glycogen were not different among groups (Supplementary Table S4 ). Periischaemic administration of sevoflurane (P¼0.009) but not propofol (P¼0.28) markedly reduced ceramide formation ( Supplementary Fig. S2 ). Intralipid administration increased long-chain acylcarnitines (P≤0.023) and hydroxyacylcarnitines (P¼0.027; Supplementary Tables S5 and S6 ) and markedly reduced the cardiac energy charge (P¼0.012; Supplementary Table S7 ).
Discussion
In this study, we used the working rat heart model, which allows the measurement of metabolic flux rates under carefully controlled conditions of energy substrate supply and physiological workload. Under aerobic conditions, more than 70% of cardiac energy requirements is provided by fatty acids 1 12 with the remainder coming from glucose and to a much lesser degree from lactate/pyruvate or amino acids. The inclusion of palmitate in the perfusate is an important aspect of this study as it permits assessment of myocardial substrate preference, a key determinant of the ability of cardiac muscle to recover after ischaemia. During ischaemia-reperfusion, metabolic flexibility (i.e. switching from one to the alternative substrate) is virtually lost whereby the more rapid recovery of FOX inhibits the rates of GOX. 13 14 The results of our study now provide evidence that sevoflurane, in contrast to propofol, reduces FOX and concomitantly increases GOX during reperfusion. These notions extend our recent findings from aerobically perfused working hearts, where we demonstrated that sevoflurane reduces FOX by decreasing fatty acid uptake at the sarcolemma and increases net GOX. 3 There is ample evidence of a close and causal relationship between cardiac metabolism and contractility, mainly from clinical studies in patients with inherited deficiencies of metabolic enzymes 15 and more recently from studies with genetically modified mice. 16 Moreover, effects of metabolic interventions on mechanical function support the concept that energy metabolism indeed is a critical factor in the haemodynamic deterioration of the failing heart. Overexpression of GLUT1, the glucose transporter responsible for basal insulin-independent cellular glucose uptake, delays progression to failure after aortic constriction in murine hearts. 16 On the other hand, inhibition of FOX via sarcolemmal (CD36) 17 or mitochondrial (CPT1) fatty acid uptake 18 , and acetyl-CoA production (C) during reperfusion in untreated hearts (IR, n¼5) or in hearts that were exposed to sevoflurane (2 vol%, SEVO+IR, n¼5), propofol (100 mM, PROP100+IR, n¼6), or Intralipid (INTRA100+IR, n¼4). P-values were computed using non-parametric tests.
ubiquinone complex II of the respiratory chain. 20 Also, fourcarbon units as derived from glucose metabolism increase the concentrations of citric acid cycle intermediates allowing more efficient oxidation of two-carbon units. Secondly, FOX couples less efficiently electron with proton flux ('uncoupling') in mitochondria, thereby increasing the formation of reactive oxygen species. 21 Thirdly, increased FOX uncouples glycolysis from GOX and enhances H + formation. 22 We have previously reported on the physiological importance of sevoflurane-mediated fuel shifts in patients undergoing off-pump coronary artery bypass graft surgery. 4 In that study, sevoflurane-induced attenuation of transcripts involved in FOX closely correlated with improved cardiac contractility. The results of the present study extend our previous findings and reveal that the long-term transcriptional metabolic remodelling by sevoflurane is indeed a true mirror of its short-term metabolic phenotype. In the current study, sevoflurane-mediated increase in GOX is likely to be the result of increased GLUT4 expression in lipid rafts, since the activity of the master switch enzyme of GOX, the PDC, was unaffected by sevoflurane. GLUT4 is the insulin-sensitive glucose transporter of the heart, which is translocated from intracellular compartments, mainly endosomes, to sarcolemmal caveolae, 23 in response to increased cardiac contractility, insulin stimulation, or activation of AMPK due to metabolic stress. 24 25 Our results
show that the increased GLUT4 expression in sevofluranetreated hearts is independent of AMPK activation, but since GLUT4 translocation is contractility-dependent, the increased GLUT4 expression in sevoflurane-treated hearts could be a consequence of the improved contractility rather than a cause. However, the ability of sevoflurane in aerobically perfused hearts to relatively increase net GOX by decreasing FOX, while maintaining GLUT4 expression in lipid rafts at a lower contractility (negative inotropy), rather implies that enhanced glucose uptake and oxidation may be at least partly contributing to the improved functional recovery in sevoflurane-treated hearts. Inhibition of fatty acid uptake and oxidation are known to increase GLUT4 expression via the glucose-fatty acid cycle ('Randle cycle'). 1 26 Moreover, long-chain CoAs and triglycerides may activate several serine kinases that inhibit insulin action. 27 In our study, sevoflurane also decreased the formation of ceramides, which are known to mediate insulin resistance by inhibiting protein kinase B. 28 Inhibition of serine palmitoyltransferase, the ratelimiting enzyme in ceramide synthesis, reduces FOX but concomitantly increases GOX. 29 During ischaemia -reperfusion, ceramides also accumulate in lipid rafts, 30 which might affect GLUT4 function. Using microdialysis probes, Carles and colleagues 31 showed a better availability of glucose in the skeletal muscle of patients during ischaemia and reperfusion after sevoflurane exposure. This is in line with observations from skeletal muscle cells, showing that sevoflurane enhances glucose uptake through activation of tyrosine kinases. 32 Collectively, sevoflurane potentially improves insulin signalling in the heart. In our study, sevoflurane also markedly reduced the accumulation of triglycerides and ceramides in the post-ischaemic heart. Beside their insulin-antagonistic effects, ceramides promote inflammation, increase mitochondrial Ca 2+ , and impair mitochondrial respiration. 33 34 On the other hand, long-chain and hydroxyacylcarnitines, typical markers of a dysfunctional fatty acid metabolism, 35 accumulated in Intralipid-treated hearts. Acylcarnitines are increased in ischaemic hearts due to inhibition of b-oxidation and may worsen intracellular Ca 2+ overload. 36 Amphiphilic acylcarnitines are further capable of inhibiting mitochondrial ATP-dependent potassium channels 37 and 'acylate' essential metabolic enzymes.
Hence, it is not surprising that we observed a significant decrease in energy charge in Intralipid-treated hearts. Reduced mitochondrial respiration as evidenced by lower acetyl-CoA turnover in sevoflurane-treated hearts resembles a state of 'metabolic hibernation', previously identified as a typical feature of the preconditioned protected state of the heart. 38 Volatile anaesthetics such as sevoflurane activate ATP-dependent potassium channels, a key player in the preconditioning process, 8 which is tightly regulated by intermediary metabolism. In this regard, it is interesting to note that sevoflurane did not alter cardiac glycogen stores, despite the well-known activation of glycogen synthase kinase-3b by volatile anaesthetics. 39 However, the glycogensalvaging effects by sevoflurane may be only seen after more extended ischaemic periods. Although previous work suggests that brief sevoflurane preconditioning increases phosphorylation of AMPK during reperfusion, 40 in our protocols where sevoflurane was administered during the entire experimental protocol, no increase in AMPK phosphorylation was observed. Nonetheless, our data lend further support to the concept of a tight interplay among energy metabolism, preconditioning, and cardioprotection. Our study has several limitations. In our analyses, we focused on the intrinsic metabolic effects of the two anaesthetics and Intralipid. Hence, we compared sevofluranetreated hearts with untreated control hearts, and since Intralipid-treated hearts also exhibited some changes in metabolites, propofol-treated hearts were compared with both untreated and Intralipid-treated hearts as described previously. 3 A direct comparison between sevoflurane-and propofol-treated hearts would not have allowed delineating the specific metabolic effects of these pharmacological agents and linking them to cardiac function and Ca 2+ overload. Although we did not observe significant cardioprotection in propofol-treated hearts in our experiments, we cannot exclude some protection with 100 mM propofol or other concentrations in other experimental settings. In fact, propofol is known to have Ca 2+ channel-blocking activities and baseline and changes in diastolic Ca 2+ concentrations tended to be lower in the propofol group ( Fig. 2 ; Supplementary Table S2 ). However, ischaemic Ca 2+ concentrations and changes in systolic Ca 2+ concentrations were not different from untreated hearts. Irrespectively, the failure of propofol to improve post-ischaemic cardiac function is unlikely to be due to its negative inotropic effects since propofol (100 mM) did not suppress cardiac contractility under aerobic conditions. Rather the increased Ca 2+ overload in propofol-treated hearts suggests the ischaemic damage as cause for the poor recovery. Finally, since the effects of propofol on rat myocardium may be different from those on human myocardium, we should be careful in extending the current results to human hearts.
In conclusion, this study demonstrates that enhanced glucose uptake via GLUT4 fuels fast recovery from Ca 2+ overload after ischaemia -reperfusion injury in sevofluranetreated hearts. Our current experimental results confirm previous clinical findings 4 5 41 in a well-controlled physiological model and shed new light on the potentially cardioprotective metabolic effects of sevoflurane.
